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© 2009 The Japan Society of Histochemistry and Cy- Microsomal prostaglandin E2 synthase-1 (mPGES-1) is an inducible enzyme that catalyzes
the conversion of prostaglandin (PG) H2 to PGE2 in downstream of cyclooxygenase-2 (COX-
2). Recent studies have obtained in vitro evidence that PGE2 participates in carcinogenesis,
angiogenesis, and induction of matrix metalloproteinase-9 (MMP-9), which plays a crucial
role in cancer invasion. However, implications for mPGES-1 in thyroid carcinomas remain
to be determined. To address this issue, we performed an immunohistochemical analysis for
mPGES-1, COX-2 and MMP-9 in 20 papillary thyroid carcinoma (PTC) patients. mPGES-1
immunoreactivity was localized in the cytoplasm of carcinoma cells in 19 cases, with an in-
tensity that tended to be distinct at the interface between the tumor and the surrounding non-
neoplastic tissue. Staining was more intense in regions with papillary arrangement, while it
was less intense in regions with trabecular or solid arrangement. In many cases, immuno-
histochemical localization of COX-2 and MMP-9 resemble that of mPGES-1. Taken together,
our results suggest the involvement of mPGES-1 in proliferation and differentiation of PTC
as well as local invasion of PTC.
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I. Introduction
Recent studies have obtained in vitro evidence that
prostaglandin E2 (PGE2) participates in carcinogenesis [1,
14, 17, 20] and angiogenesis [16, 18]. The biosynthesis of
PGE2 requires three sequential enzymic reactions: the
release of arachidonic acid from membrane glycerophospho-
lipids by phospholipase A2, the conversion of arachidonic
acid to the unstable intermediate PGH2 by cyclooxygenase-
1 (COX-1) or cyclooxygenase-2 (COX-2), and the isomer-
ization of PGH2 to PGE2 by PGE2 synthase (PGES) [EC
5.3.99.3] (Fig. 1). COX-2 and PGES collaboratively medi-
ate the induction of matrix metalloproteinase-9 (MMP-9)
[2], which plays a crucial role in cancer invasion by base-
ment membrane degradation [8].
It has been shown that COX-2 is involved in the patho-
mechanisms of thyroid carcinomas and chronic thyroiditis
(CT) [4, 11]. However, implications for PGES in thyroid
carcinomas remain to be determined. To address this issue,
we performed an immunohistochemical analysis for mem-
brane-bound PGES-1 (mPGES-1), a well characterized iso-
form of PGES, as well as COX-2 and MMP-9, in surgically
resected thyroid gland tissues including papillary thyroid
carcinoma (PTC).
II. Materials and Methods
Subjects and tissue preparation
This investigation was carried out on archival, formalin
(20%)-fixed, paraffin-embedded materials of 20 sporadic
PTC patients who underwent thyroidectomy, at TokyoOmi et al. 106
Women’s Medical University Hospital. This study was per-
formed after obtaining written informed consent from the
patients examined.
Primary antibodies
The primary antibodies employed in immunohisto-
chemistry were rabbit polyclonal IgG against mPGES-1
(Cayman Chemical, Ann Arbor, MI, USA; diluted 1:300),
rabbit polyclonal IgG against COX-2 (Cayman Chemical;
diluted 1:300), and mouse monoclonal IgG against MMP-9
(Daiichi Fine Chemical, Toyama, Japan; diluted 1:500).
Immunohistochemical analysis
Multiple 3-μm-thick sections of each material were
used for hematoxylin-eosin staining and immunohistochem-
ical staining. For the latter staining, sections were deparaf-
finized, rehydrated, quenched for 5 min at room temperature
with 3% H2O2, rinsed in phosphate-buffered saline (PBS),
pH 7.6, processed with microwaving (95°C, 400 W, 20 min)
in 10 mM citrate buffer, pH 6.0 for mPGES-1 and MMP-9
staining and 1 mM ethylenediamine N,N,N’,N’-tetraacetic
acid, pH 8.0 for COX-2, pretreated for 30 min at room tem-
perature with 3% nonimmune animal serum in PBS, and
then incubated overnight at 4°C with the primary antibodies.
Antibody binding was visualized by the avidin-biotin-
immunoperoxidase complex method using the appropriate
Vectastain ABC kits (Vector Laboratories, Burlingame, CA,
USA) according to the manufacturer’s instructions, with
3,3'-diaminobenzidine tetrahydrochloride and hematoxylin
as the chromogen and the counterstain, respectively. Sec-
tions from which the primary antibodies were omitted or
sections which were incubated with nonimmune serum
derived from the same animal species as those producing
the antibodies served as negative reaction controls.
III. Results
Of the 20 PTC cases, 19 showed focal strong mPGES-
1 immunoreactivity, while the other one showed diffuse
weak immunoreactivity. The immunoreactivity was local-
ized in the cytoplasm of carcinoma cells in all of the PTC
cases, and was prominent at the interface between the tumor
and the surrounding non-neoplastic parenchyma (Fig. 2B, E,
H). Staining was more intense in regions displaying stromal
invasion with papillary arrangement (Fig. 3A), and by con-
trast it was less intense in regions displaying trabecular ar-
rangement (Fig. 3B) and solid nest formation (Fig. 3C). In
many cases, immunohistochemical localization of COX-2
(Fig. 2A, D, G) and MMP-9 (Fig. 2C, F, I) resembled that of
mPGES-1. However, immunoreactivities for COX-2 and
MMP-9 were diffuse and uniform in PTC cells of 13 cases
and four cases, respectively; of the latter four cases, the
mPGES-1 immunoreactivity was weak in one case and
strong in three cases. Of the 20 PTC cases, seven were with
CT, and the rest were not associated with any other thyroid
disease. In the seven CT cases, non-neoplastic thyroid
parenchyma demonstrated scattered formation of lymph
follicles and swelling of follicular epithelial cells that often
had eosinophilic cytoplasm and showed papillary arrange-
ment. Immunoreactivities for mPGES-1 and MMP-9 were
detected in germinal center lymphocytes and papillary-
arranged follicular epithelial cells in five cases (Fig. 4A–C),
but were undetectable in intact follicular epithelial cells in
all of the CT cases. Immunohistochemical localization of
COX-2 was similar to that of mPGES-1 and MMP-9 in
three CT cases (Fig. 4A–C). Normal thyroid parenchyma
did not show any marked staining for mPGES-1, COX-2 or
MMP-9 (Fig. 4A–C).
IV. Discussion
To date, three isoforms of PGES have been identified in
mammalians: mPGES-1, mPGES-2 and cytosolic PGES
(cPGES) [7, 9]. mPGES-1 is localized in the microsomal
membrane, induced by proinflammatory stimuli, and acts in
concert with COX-2 to maintain and amplify inflammatory
activity. mPGES-2 is localized in the Golgi apparatus mem-
brane,  constitutively  expressed,  and  functionally  coupled
with COX-1 and COX-2. cPGES is localized in the cytosol,
constitutively expressed, and functionally linked to COX-1.
Fig. 1. Schematic diagram of the COX-2/PGES-1 catalyzed PGE2 bio-
synthesis pathway in carcinoma invasion. COX-2, cyclooxygenase-
2; MMP-9, matrix metalloproteinase-9; PGE2, prostaglandin E2;
PGES, membrane-bound prostaglandin E2 synthase.PGES in Papillary Thyroid Carcinoma 107
Thus, as our results indicated, it is conceivable that the
inducible isoform mPGES-1 immunoreactivity was focally
prominent in PTC lesions, suggesting that the levels of
mPGES-1 induction stimuli vary in the sites of the lesions.
Previous studies have indicated the overexpression of
mPGES-1 in cancers of the lung [21], colon [22], stomach
[19],  head  and  neck  [3],  endometrium  [6],  and  penis  [5].
However, there is no precedent showing immunohisto-
chemical detection of PGES in thyroid tissues, and this is the
first report showing mPGES-1 expression in PTC. Several
studies have documented the pathological actions of PGE2
as a PGES product. PGE2 activates epidermal growth factor
receptor [14], peroxisome proliferator-activated receptor δ
[20], and Wnt signaling [1] in carcinogenesis. PGE2 also
induces expression of vascular endothelial growth factor,
basic fibroblast growth factor, and MMP-9 in carcinoma
cells and stromal cells through PGE receptor EP2 that
promotes cancer angiogensis [16, 18]. Thus, the COX-2/
mPGES-1-catalyzed PGE2 production cascade has been of
great interest to oncologists as a possible therapeutic target.
It is known that CT increases risk of the pathogenesis of
PTC in a proportion varying from 10 to 40% [12, 13]. A
recent study demonstrated the upregulation of COX-2 in
both PTC and CT lesions, suggesting the involvement of
inflammatory processes in carcinogenesis [4, 11]. In rela-
tion to this, it is noteworthy that our study showed that both
COX-2 and mPGES-1 were restricted to these lesions but
undetectable in morphologically intact thyroid parenchyma.
Our finding of the colocalization of mPGES-1 with MMP-9
at the interface between the tumor and the surrounding non-
Fig. 2. Photomicrographs of PTC tissue sections immunostained for COX-2 (A, D, G), mPGES-1 (B, E, H) and MMP-9 (C, F, I). Series of
panels (A–C), (D–F) and (G–I) indicate the same regions including the interface between PTC tissue (each right half) and non-neoplastic
thyroid parenchyma (each left half) on consecutive sections, respectively. Bars=1 mm (A–C), 500 µm (D–F), 100 µm (G–I). ABC method
using DAB. ABC, avidin-biotin-immunoperoxidase complex; DAB, 3,3'-diaminobenzidine tetrahydrochloride; PTC, papillary thyroid carcinoma.Omi et al. 108
neoplastic tissue suggests a close link between these two en-
zymes. This supports in vitro evidence that the mPGES-1
product PGE2 induces MMP-9 [2], which contributes to
carcinoma invasion [8].
Another intriguing finding that mPGES-1 expression
levels were greater in PTC cells displaying papillary ar-
rangement compared to those showing trabecular or solid
arrangement points to the possibility that mPGES-1 up-
regulation may be involved in the differentiation of PTC;
papillary arrangement may indicate the state of well differ-
entiation of carcinoma, while trabecular or solid arrange-
ment may indicate the state of poor differentiation. It has
been shown that RET/PTC rearrangement is detectable in
approximately 30% of the adult sporadic PTC cases [10].
Intracellular tyrosine kinase domain of RET is coupled
with an N-terminal fragment of various unrelated genes,
and RET/PTC rearrangement occurs in the early step of
carcinogenesis of PTC. The two most common rearrange-
ment types, RET/PTC1 and RET/PTC3, upregulate COX-2
and mPGES-1 expression levels in cultured thyroid cells
[15]. These observations suggest that mPGES-1 expression
triggers PTC carcinogenesis. Finally, it remains to be deter-
mined whether mPGES-1 expression levels may have
relevance to the prognosis of PTC via direct invasion or
hematogenous or lymphogenous metastasis. The answers
to this and other questions concerning the establishment of
therapeutic strategies will require further investigations.
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Fig. 3. Photomicrographs of PTC lesions immunostained for PGES-1. Panels (A), (B) and (C) indicate foci of papillary arrangement, trabecular
arrangement, and solid nest formation of PTC, respectively. Panel (A) is from the interface of stromal invasion, and panels (B) and (C) are from
the central core of a tumor. Bars=100 µm. ABC method using DAB. ABC, avidin-biotin-immunoperoxidase complex; DAB, 3,3'-diamino-
benzidine tetrahydrochloride; PTC, papillary thyroid carcinoma.
Fig. 4. Photomicrographs of CT lesions immunostained for COX-2 (A), mPGES-1 (B) and MMP-9 (C). Immunoreactivities for COX-2 (A),
mPGES-1 (B) and MMP-9 (C) were detected in germinal center lymphocytes (asterisks) and papillary-arranged follicular epithelial cells
(arrows) but undetectable in intact follicular epithelial cells (each left upper side). Bars=200 µm. ABC method using DAB. ABC, avidin-biotin-
immunoperoxidase complex; CT, chronic thyroiditis; DAB, 3,3'-diaminobenzidine tetrahydrochloride; PTC, papillary thyroid carcinoma.PGES in Papillary Thyroid Carcinoma 109
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